Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 382-389

  Hsu, Tsai Ching ^a   Huang, Chih Yang ^b,c   Chiang, Szu Yi ^d   Lai, Wen Xian ^a   Tsai, Chang Hai ^c   Tzang, Bor Show ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d Hualien Hospital   (Taiwan)

Author keywords

Cystamine; Liver; NZB W F1 mice; Systematic lupus erythematosus (SLE)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; CYSTAMINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEAT SHOCK PROTEIN 70; LIVER PROTEIN; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME ASSAY; FEMALE; HEPATITIS; IMMUNOBLOTTING; LIVER DISEASE; MOUSE; NEPHELOMETRY; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CYSTAMINE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; IMMUNOBLOTTING; INFLAMMATION; LIVER; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; NEPHELOMETRY AND TURBIDIMETRY; PROTEINS; TRANSGLUTAMINASES;

EID: 37549043603     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.059     Document Type: Article

References (46)

1. Abiru S., Nakao K., Ichikawa T., Migita K., Shigeno M., Sakamoto M., Ishikawa H., Hamasaki K., Nakata K., and Eguchi K. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35 (2002) 1117-1124
2. Abraham S., Begum S., and Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann. Rheum. Dis. 63 (2004) 123-129
3. Botzler C., Kolb H.J., Issels R.D., and Multhoff G. Noncytotoxic alkyl-lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cells. Int. J. Cancer 65 (1996) 633-638
4. Chan C.C., and Rodger I.W. Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases. Adv. Exp. Med. Biol. 407 (1997) 157-161
5. Conroy S.E., Tucker L., Latchman D.S., and Isenberg D.A. Incidence of anti Hsp 90 and 70 antibodies in children with SLE, juvenile dermatomyositis and juvenile chronic arthritis. Clin. Exp. Rheumatol. 14 (1996) 99-104
6. Denman A.M., Denman E.J., and Holborow E.J. Suppression of Coombs-positive haemolytic anaemia in NZB mice by antilymphocyte globulin. Lancet 1 7499 (1967) 1084-1086 (May 20)
7. Dhillon V.B., McCallum S., Norton P., Twomey B.M., Erkeller-Yuksel F., Lydyard P., Isenberq D.A., and Latchman D.S. Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus. Ann. Rheum. Dis. 52 (1993) 436-442
8. Folk J.E. Transglutaminases. Annu. Rev. Biochem. Allied Res. 49 (1980) 517-531
9. Fung H.B., and Kirschenbaum H.L. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin. Ther. 21 (1999) 1131-1157
10. Gaipl U.S., Kuhn A., Sheriff A., Munoz L.E., Franz S., Voll R.E., Kalden J.R., and Herrmann M. Clearance of apoptotic cells in human SLE. Curr. Dir. Autoimmun. 9 (2006) 173-187
11. Grossmayer G.E., Munoz L.E., Gaipl U.S., Franz S., Sheriff A., Voll R.E., Kalden J.R., and Herrmann M. Removal of dying cells and systemic lupus erythematosus. Mod. Rheumatol. 15 (2005) 383-390
12. Hahn B.H. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace D.J., and Hahn B.H. (Eds). Dubois' lupus erythematosus (1993), Williams and Wilkins, Philadelphia 69-76
13. Herkel J., Mimran A., Erez N., Kam N., Lohse A.W., Marker-Hermann E., Rotter V., and Cohen I.R. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J. Autoimmun. 17 (2001) 63-69
14. Herlong H.F. Approach to the patient with abnormal liver enzymes. Hosp. Pract. (Off. Ed.) 29 (1994) 32-38
15. Holborow E.J., and Denman A.M. Autoimmune disease in inbred mice. Clin. Exp. Immunol. 2 (1967) 761-767 (Dec, Suppl)
16. Hsu T.C., Chiang S.Y., Huang C.Y., Yang C.W., Huang C.N., and Tzang B.S. Beneficial effects of treatment with transglutaminases inhibitor cystamine on macrophage response in NZB/W F1 mice. Exp. Biol. Med. (Maywood) 232 (2007) 195-203
17. Ientile R., Campisi A., Raciti G., Caccamo D., Curro M., Cannavo G., Li V.G., Macaione S., and Vanella A. Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells. J. Neurosci. Res. 74 (2003) 52-59
18. Jeitner T.M., Delikatny E.J., Ahlqvist J., Capper H., and Cooper A.J. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. 69 (2005) 961-970
19. Kanzler S., and Galle P.R. Apoptosis and the liver. Semin. Cancer Biol. 10 (2000) 173-184
20. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., and Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8 (2002) 143-149
21. Kiang J.G., and Tsokos G.C. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol. Ther. 80 (1998) 183-201
22. Kuhn H.M., Kromminga A., Flammann H.T., Frey M., Layer P., and Arndt R. p53 autoantibodies in patients with autoimmune diseases: a quantitative approach. Autoimmunity 31 (1999) 229-235
23. Kushner I., Rzewnicki D., and Samols D. What does minor elevation of C-reactive protein signify?. Am. J. Med. 119 166 (2006) e17-e28
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-684
25. Lesort M., Lee M., Tucholski J., and Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278 (2003) 3825-3830
26. Lorand L., and Conrad S.M. Transglutaminases. Mol. Cell. Biochem. 58 (1984) 9-35
27. Lu M.C., Li K.J., Hsieh S.C., Wu C.H., and Yu C.L. Lupus-related advanced liver involvement as the initial presentation of systemic lupus erythematosus. J. Microbiol. Immunol. Infect. 39 (2006) 471-475
28. Miret C., Molina R., Filella X., Garcia-Carrasco M., Claver G., Ingelmo M., Ballesta A., and Font J. Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity. Tumour Biol. 24 (2003) 185-188
29. Mishra S., and Murphy L.J. The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem. Biophys. Res. Commun. 339 (2006) 726-730
30. Mok C.C., and Lau C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 56 (2003) 481-490
31. Moseley P. Stress proteins and the immune response. Immunopharmacology 48 (2000) 299-302
32. Mukai M., Bohgaki T., Notoya A., Kohno M., Tateno M., and Kobayashi S. Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus. Lupus 9 (2000) 74-77
33. Nagy G., Koncz A., and Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 25 (2005) 123-140
34. Ripley B.J., Isenberg D.A., and Latchman D.S. Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90. J. Autoimmun. 17 (2001) 341-346
35. Roigas J., Wallen E.S., Loening S.A., and Moseley P.L. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. Adv. Exp. Med. Biol. 451 (1998) 225-229
36. Russell A.S., and Denman A.M. Normal induction and maintenance of tolerance in (NZBxNZW) F1 mice. Clin. Exp. Immunol. 5 3 (1969) 265-272 (Sep)
37. Selzer F., Sutton-Tyrrell K., Fitzgerald S., Tracy R., Kuller L., and Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37 (2001) 1075-1082
38. Shucard J.L., Gaines J.J., Ambrus Jr. J., and Shucard D.W. C-reactive protein and cognitive deficits in systemic lupus erythematosus. Cogn. Behav. Neurol. 20 (2007) 31-37
39. Szondy Z., Sarang Z., Molnar P., Nemeth T., Piacentini M., Mastroberardino P.G., Falasca L., Aeschlimann D., Kovacs J., Kiss I., Szegezdi E., Lakos G., Rajnavolgyi E., Birckbichler P.J., Melino G., and Fesus L. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7812-7817
40. Tilley S.L., Coffman T.M., and Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108 (2001) 15-23
41. Villalobos-Hurtado R., Sanchez-Rogriguez S.H., Avalos-Diaz E., and Herrera-Esparza R. Possible role of Hsp70 in autoantigen shuttling to the dermo-epidermal junction in systemic lupus erythematosus. Reumatismo 55 (2003) 155-158
42. Weinberg J.B. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol. Res. 22 (2000) 319-341
43. Wu T., Han C., Lunz III J.G., Michalopoulos G., Shelhamer J.H., and Demetris A.J. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology 36 (2002) 363-373
44. Yu J., Ip E., Dela Pena A., Hou J.Y., Sesha J., Pera N., Hall P., Kirsch R., Leclercq I., and Farrell G.C. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 43 (2006) 826-836
45. Zein N., Ganuza C., and Kushner I. Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum. 22 (1979) 7-12
46. Zhang N., Ahsan M.H., Zhu L., Sambucetti L.C., Purchio A.F., and West D.B. NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation. J. Biol. Chem. 280 (2005) 21400-21408